Navicixizumab

Mereo BioPharma's CEO, Dr. Denise Scots-Knight, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on Nov. 19, 2024. The company focuses on developing therapeutics for rare diseases, including setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease. Mereo also has oncology product candidates in clinical development.

Mereo BioPharma reports $80.5 million cash as of Sept 30, 2024, expected to fund operations into 2027. Setrusumab receives Breakthrough Therapy designation from the FDA for osteogenesis imperfecta treatment. Alvelestat expected to be Phase 3-ready by end of 2024.

Mereo BioPharma's CEO, Dr. Denise Scots-Knight, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on September 18. The company focuses on rare diseases, with product candidates setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease. Mereo also has oncology candidates etigilimab and navicixizumab in development.

Mereo BioPharma announced CEO Dr. Denise Scots-Knight will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The company focuses on rare diseases, with key products setrusumab and alvelestat, and has partnerships for development and commercialization. Forward-looking statements caution about risks and uncertainties in clinical development and business operations.